Jump to content
Content on WikiMesothelioma is reviewed by three named attorneys at Danziger & De Llano LLP prior to publication. See our editorial standards.

Heated Chemotherapy HITHOC and HIPEC: Difference between revisions

From WikiMesothelioma — Mesothelioma Knowledge Base
← Older edit
MesotheliomaSupport (talk | contribs)
Bots, Bureaucrats, Interface administrators, Administrators
3,256 edits
VisualWikitext
Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)
SEO cleanup: converting duplicate page to redirect
Tag: New redirect
 
Line 1: Line 1:
{{#seo:
#REDIRECT [[Heated Chemotherapy (HITHOC and HIPEC)]]
|title=Heated Chemotherapy for Mesothelioma: HITHOC and HIPEC Procedures, Survival Data & Eligibility
|description=Comprehensive guide to hyperthermic chemotherapy for mesothelioma including HITHOC for pleural disease and HIPEC for peritoneal mesothelioma with survival outcomes, patient selection criteria, and clinical trial data.
|keywords=HITHOC, HIPEC, heated chemotherapy mesothelioma, hyperthermic intrathoracic chemotherapy, hyperthermic intraperitoneal chemotherapy, CRS-HIPEC peritoneal mesothelioma, cisplatin heated perfusion, mesothelioma surgery
|author=David Foster, Patient Advocate, Danziger & De Llano
|published_time=2026-02-19
}}
{| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Heated Chemotherapy Profile
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" | HITHOC (Pleural) & HIPEC (Peritoneal)
|-
| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" | Category
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Treatment
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Temperature Range
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''40–43°C'''
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Primary Agent
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cisplatin
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | HITHOC Survival
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''20.5 months''' (median)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | HIPEC Survival
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''53 months''' (median)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | HIPEC 5-Year OS
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''47%'''
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Perfusion Duration
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 60–120 minutes
|-
| style="padding:10px; font-weight:bold;" | 30-Day Mortality
| style="padding:10px;" | 2–4%
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | <span data-nosnippet class="noai-content">[https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]</span>
|}
 
'''Heated chemotherapy''' represents one of the most significant advances in mesothelioma treatment, combining cytoreductive surgery with high-concentration chemotherapy solutions heated to '''40–43°C''' and circulated directly within the body cavity where the tumor originated. Two distinct procedures have emerged for the two primary forms of mesothelioma: '''Hyperthermic Intrathoracic Chemotherapy (HITHOC)''' for [[Pleurectomy_and_Decortication|pleural mesothelioma]] and '''Hyperthermic Intraperitoneal Chemotherapy (HIPEC)''' for peritoneal mesothelioma.<ref name="pmc_hipec_rationale" /><ref name="dandell_treatment" />
 
The scientific rationale is compelling: hyperthermia selectively destroys cancer cells at temperatures that normal tissue can tolerate, while simultaneously increasing drug penetration from approximately '''1–2 mm to up to 5 mm''' into tumor tissue. For pleural mesothelioma, a '''National Cancer Database''' analysis of '''3,232 patients''' found HITHOC independently improved overall survival ('''HR 0.80''', p=0.002), with a median of '''20.5 months''' versus 16.8 months without HITHOC. For peritoneal mesothelioma, '''CRS-HIPEC''' has transformed outcomes from a median survival of under 12 months to '''53 months''' in the landmark multi-institutional registry, with '''5-year survival rates reaching 47%'''.<ref name="jtd_ncdb" /><ref name="jco_yan" /><ref name="mlc_treatment" />
 
At experienced high-volume centers, '''30-day mortality''' for both HITHOC and HIPEC ranges from '''2% to 4%''', and patients achieving complete cytoreduction with HIPEC have achieved median survival exceeding '''10 years'''. The completeness of tumor removal and histologic subtype remain the most powerful predictors of outcome for both procedures.<ref name="wake_forest" /><ref name="mesonet_treatment" />
 
'''Heated chemotherapy at a glance:'''
* '''HITHOC vs HIPEC''' — HITHOC targets the thoracic cavity for pleural mesothelioma while HIPEC targets the abdominal cavity for peritoneal disease, but both use the same 40–43°C hyperthermic perfusion principle<ref name="pmc_hipec_rationale" />
* '''Hyperthermic vs normothermic drug penetration''' — cisplatin penetrates approximately 5 mm into tumor tissue at 42°C compared to only 1–2 mm at normal body temperature, a 3–5 fold increase<ref name="pmc_optimal_hipec" />
* '''Cancer cells vs normal tissue''' — malignant cells are selectively destroyed at 41–43°C while healthy tissue tolerates up to 45°C, creating a therapeutic window unavailable with systemic chemotherapy<ref name="pmc_hithoc_mech" />
* '''HITHOC survival vs surgery alone''' — NCDB propensity-matched analysis of 3,232 patients showed 20.5-month median survival with HITHOC versus 16.8 months without, a 20% mortality reduction<ref name="jtd_ncdb" />
* '''HIPEC vs historical peritoneal outcomes''' — CRS-HIPEC achieved 53-month median survival and 47% 5-year rates in the 405-patient landmark registry compared to under 12 months with systemic chemotherapy alone<ref name="jco_yan" />
* '''Complete vs incomplete cytoreduction''' — CC-0/CC-1 resection with cisplatin HIPEC produced 127-month median survival at Wake Forest versus only 3 months for incomplete R2c resection<ref name="wake_forest" />
* '''Low vs high PCI scores''' — patients with Peritoneal Cancer Index of 20 or below achieved 119-month median survival compared to 39 months when PCI exceeded 20<ref name="cureus_india" />
* '''Cisplatin vs cisplatin-doxorubicin HIPEC''' — dual-agent HIPEC regimens achieved significantly better survival than single-agent protocols in the RENAPE multicenter study<ref name="pmc_crs_hipec_review" />
* '''Low-dose vs high-dose cisplatin''' — cisplatin above 125 mg/m2 carries 2.7-fold higher nephrotoxicity risk compared to lower doses, making dosing optimization critical<ref name="pmc_hitoc_german" />
* '''Surgery alone vs surgery plus immunotherapy synergy''' — preclinical 2024 data shows HITHOC enhances T-cell infiltration and checkpoint inhibitor response compared to surgery without hyperthermic perfusion<ref name="aacr_immuno" />
 
== Key Facts ==
 
{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Metric
! style="background:#1a5276; color:white; padding:10px;" | Finding
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | HITHOC median survival (NCDB, n=3,232)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 20.5 months with HITHOC vs 16.8 months without; HR 0.80, 95% CI 0.69–0.92, p=0.002<ref name="jtd_ncdb" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | HIPEC median survival (Yan et al., n=405)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 53 months median OS with 47% 5-year overall survival across 8 international centers<ref name="jco_yan" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | Complete cytoreduction survival (Wake Forest, n=111)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | CC-0/CC-1 with cisplatin HIPEC: 127-month median OS vs 3.0 months for R2c incomplete resection<ref name="wake_forest" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | CC-0 vs CC-1 vs CC-2 vs CC-3
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 94 months vs 67 months vs 40 months vs 12 months median OS by cytoreduction completeness<ref name="pmc_crs_hipec_review" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | PCI threshold effect (India tertiary, n=15)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | PCI ≤20: 119-month median OS vs PCI >20: 39-month median OS<ref name="cureus_india" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | German multicenter HITHOC registry (n=350)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 4 university centers (Regensburg, Munich, Heidelberg, Freiburg); 86% macroscopic complete resection; 3.7% 30-day mortality<ref name="pmc_hitoc_german" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | Epithelioid subgroup HITHOC benefit (pilot RCT, n=27)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 45 months with HITHOC vs 15 months without; 3-fold survival advantage; HR 0.77 overall<ref name="medrxiv_pilot" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | Cisplatin vs mitomycin C for HIPEC (Wake Forest)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cisplatin 42.4-month median OS vs mitomycin C 11.6 months, p=0.007<ref name="wake_forest" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | Dual-agent vs single-agent HIPEC (RENAPE, n=249)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Dual-agent HR 0.54, 95% CI 0.31–0.95 for overall survival without increased major morbidity<ref name="pmc_crs_hipec_review" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | High-dose cisplatin nephrotoxicity (>125 mg/m2)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2.7-fold higher renal insufficiency risk, p=0.006; 12.2-fold higher in-hospital mortality risk, p=0.001<ref name="pmc_hitoc_german" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6; font-weight:bold;" | 30-day mortality at high-volume centers
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HITHOC 3.2–3.7%; HIPEC 2.0–2.7% across major registries<ref name="jtd_ncdb" /><ref name="jco_yan" /><ref name="wake_forest" />
|-
| style="padding:10px; font-weight:bold;" | Drug penetration enhancement
| style="padding:10px;" | Cisplatin tissue penetration increases from 1–2 mm (37°C) to approximately 5 mm (42°C) under hyperthermic conditions<ref name="pmc_optimal_hipec" />
|}
 
== What Is the Scientific Basis for Heated Chemotherapy? ==
 
The combination of hyperthermia and cytotoxic drugs produces cancer cell killing that exceeds what either treatment achieves alone. This synergism operates through multiple mechanisms that researchers have identified over decades of laboratory and clinical investigation.<ref name="pmc_hipec_rationale" /><ref name="pmc_hithoc_review" />
 
Hyperthermia disrupts tumor cell membranes, increasing their permeability and allowing chemotherapy agents to penetrate deeper into tissue. At normothermic temperatures (37°C), cisplatin penetrates approximately 1–2 mm into tumor deposits, but at hyperthermic temperatures (42°C), penetration increases to approximately 5 mm. This enhanced drug uptake is critical because mesothelioma typically grows as a diffuse sheet across serosal surfaces rather than as discrete nodules.<ref name="pmc_optimal_hipec" /><ref name="dandell_treatment" />
 
Cancer cells are selectively vulnerable to heat in the 41–43°C range due to increased lysosomal enzyme activity specific to malignant cells. Normal cells tolerate temperatures up to approximately 45°C, creating a therapeutic window. Hyperthermia also depresses oxidative metabolism in tumor cells, causing accumulation of lactic acid and decreased pH in the tumor microenvironment, which further accelerates cell death. Additionally, heat reduces chemoresistance — a major clinical problem in mesothelioma — by amplifying the cytotoxic effect of cisplatin even at temperatures below 42°C.<ref name="pmc_hipec_rationale" /><ref name="pmc_hithoc_mech" />
 
{| style="width:95%; margin:1em auto; border:1px solid #dee2e6; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "The highest thermal enhancement ratios have been observed for alkylating agents such as cisplatin, melphalan, and cyclophosphamide — the very drugs most commonly used in intraoperative perfusion protocols for mesothelioma."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Patient Advocate, Danziger & De Llano
|}
 
== How Does HITHOC Work for Pleural Mesothelioma? ==
 
HITHOC is performed immediately following cytoreductive surgery for pleural mesothelioma, most commonly [[Pleurectomy_and_Decortication|pleurectomy/decortication (P/D)]]. After the surgeon removes all visible tumor from the chest cavity, a heated chemotherapy solution is circulated through the thoracic space using a closed-circuit perfusion system. The goal is to destroy microscopic residual cancer cells that surgery alone cannot remove.<ref name="pmc_hitoc_german" /><ref name="mdpi_hitoc_2024" />
 
In the German multicenter study — the largest HITHOC dataset worldwide — 350 patients were treated across four university centers (Regensburg, Munich, Heidelberg, Freiburg) from 2008 to 2019. Extended P/D was the most common surgical approach (75% of cases), followed by standard P/D (22%) and EPP (3%). Macroscopic complete resection was achieved in 86% of patients. Additional structures resected included the diaphragm (65.7%), pericardium (44.6%), and chest wall (10%).<ref name="pmc_hitoc_german" /><ref name="mlc_surgery" />
 
=== Dosing Protocols ===
 
Cisplatin is the primary chemotherapy agent used in HITHOC, administered either alone or combined with doxorubicin:<ref name="pmc_hitoc_german" />
 
{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Regimen
! style="background:#1a5276; color:white; padding:10px;" | Patients
! style="background:#1a5276; color:white; padding:10px;" | Dosing
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cisplatin alone
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 61%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Median 108.8 mg/m² (range 51–200 mg/m²)
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cisplatin + doxorubicin
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 39%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cisplatin 108.8 mg/m² + doxorubicin 46.9 mg/m²
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Low-dose cisplatin (≤125 mg/m²)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 67%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Reduced nephrotoxicity risk
|-
| style="padding:10px;" | High-dose cisplatin (>125 mg/m²)
| style="padding:10px;" | 33%
| style="padding:10px;" | 2.7× higher renal insufficiency risk (p=0.006)
|}
 
Perfusion is typically performed for 60–90 minutes at a maximum temperature of 42°C with a perfusion volume of approximately 5,000 mL. An Egyptian comparative trial used cisplatin at 125 mg/m² infused for 70 minutes at 40–43°C.<ref name="springer_egyptian" /><ref name="pmc_egyptian" />
 
=== Survival Outcomes ===
 
Multiple studies have demonstrated a survival advantage for HITHOC when added to cytoreductive surgery:<ref name="jtd_ncdb" /><ref name="wjso_systematic" />
 
{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Study
! style="background:#1a5276; color:white; padding:10px;" | Patients
! style="background:#1a5276; color:white; padding:10px;" | With HITHOC
! style="background:#1a5276; color:white; padding:10px;" | Without HITHOC
! style="background:#1a5276; color:white; padding:10px;" | Significance
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | NCDB propensity-matched (2023)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 3,232 (365 HITHOC)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 20.5 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 16.8 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HR 0.80, p=0.002
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Systematic review (2025)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 7 studies
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 13–35 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 11–22.8 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 6 of 7 studies showed benefit
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Randomized pilot (2021)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 27
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 28 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 19 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HR 0.77
|-
| style="padding:10px;" | Epithelioid subgroup (pilot)
| style="padding:10px;" | subset
| style="padding:10px;" | '''45 months'''
| style="padding:10px;" | 15 months
| style="padding:10px;" | 3× survival advantage
|}
 
The largest analysis — a propensity-score matched study using the National Cancer Database — demonstrated that HITHOC was independently associated with improved overall survival and, notably, decreased 30-day mortality (3.2% vs. 6.0%, p=0.017) despite increased length of stay (12 vs. 7 days).<ref name="jtd_ncdb" /><ref name="mesoatty_treatment" />
 
=== Immunomodulatory Effects ===
 
Preclinical research published in 2024 demonstrated that HITHOC remodels the tumor immune microenvironment by promoting T-cell infiltration and enhancing immune checkpoint expression. In murine models, HITHOC synergized with dual PD-1 and CTLA-4 inhibition, providing a scientific rationale for combining HITHOC with [[Immunotherapy_for_Mesothelioma|immunotherapy]] in future clinical trials.<ref name="aacr_immuno" />
 
== How Does HIPEC Work for Peritoneal Mesothelioma? ==
 
CRS-HIPEC has transformed peritoneal mesothelioma from a rapidly fatal disease with median survival of 6–16 months into one where long-term survival exceeding 10 years is achievable in selected patients. The procedure involves maximal cytoreductive surgery to remove all visible tumor deposits from the peritoneal surfaces, followed by perfusion of the abdominal cavity with heated chemotherapy.<ref name="pmc_crs_hipec_review" /><ref name="wake_forest" />
 
=== The Peritoneal Cancer Index ===
 
The Peritoneal Cancer Index (PCI), developed by Sugarbaker, is the standard method for quantifying peritoneal disease burden before and during surgery. The abdomen is divided into 13 regions — 9 abdominal regions (numbered 0–8 in clockwise fashion) plus 4 small bowel segments (upper/lower jejunum, upper/lower ileum). Each region receives a Lesion Size score from 0 (no tumor) to 3 (>5 cm or confluence), producing a total PCI score from 0 to 39.<ref name="pmc_crs_hipec_review" /><ref name="dandell_peritoneal" />
 
PCI profoundly impacts prognosis: patients with PCI ≤20 achieved a median overall survival of 119 months, compared to only 39 months when PCI exceeded 20. At Wake Forest Baptist Medical Center — one of the world's highest-volume centers with 28 years of experience and 111 peritoneal mesothelioma patients — the mean PCI at first CRS-HIPEC was 18.7.<ref name="wake_forest" /><ref name="cureus_india" />
 
=== Completeness of Cytoreduction ===
 
The completeness of cytoreduction (CC) score is the single most powerful predictor of survival after CRS-HIPEC:<ref name="pmc_crs_hipec_review" /><ref name="jco_yan" />
 
{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | CC Score
! style="background:#1a5276; color:white; padding:10px;" | Residual Disease
! style="background:#1a5276; color:white; padding:10px;" | Median Survival
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | CC-0
| style="padding:10px; border-bottom:1px solid #dee2e6;" | No visible disease
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''94 months'''
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | CC-1
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Nodules <2.5 mm
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''67 months'''
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | CC-2
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Nodules 2.5 mm–2.5 cm
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 40 months
|-
| style="padding:10px;" | CC-3
| style="padding:10px;" | >2.5 cm or confluence
| style="padding:10px;" | 12 months
|}
 
CC-0 and CC-1 are considered complete cytoreductions because residual nodules ≤2.5 mm are thought to be penetrable by the heated intraperitoneal chemotherapy. At Wake Forest, patients achieving R0-R1 complete cytoreduction had a median overall survival of 127 months — more than 10 years — versus only 3.0 months for R2c (incomplete) resections.<ref name="wake_forest" /><ref name="mlc_peritoneal" />
 
=== HIPEC Agents and Protocols ===
 
{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Agent
! style="background:#1a5276; color:white; padding:10px;" | Dosing
! style="background:#1a5276; color:white; padding:10px;" | Duration
! style="background:#1a5276; color:white; padding:10px;" | Notes
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cisplatin
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 200–250 mg/m²
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 90 min
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Currently preferred first-line agent
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cisplatin + doxorubicin
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 50–100 + 15–45 mg/m²
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 90 min
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Better OS (HR 0.54) in RENAPE study
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Mitomycin C
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 30–40 mg/m²
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 90–120 min
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Earlier standard; inferior to cisplatin
|-
| style="padding:10px;" | Carboplatin
| style="padding:10px;" | 500–1,000 mg/m²
| style="padding:10px;" | 90 min
| style="padding:10px;" | Occasional alternative
|}
 
The Wake Forest group demonstrated that switching from mitomycin C to cisplatin significantly improved outcomes: median OS of 42.4 months with cisplatin versus 11.6 months with mitomycin C (p=0.007). The RENAPE multicenter study (249 patients, 20 centers) showed that dual-agent HIPEC regimens achieved significantly better overall survival than single-agent regimens (HR 0.54, 95% CI 0.31–0.95) without increased major morbidity.<ref name="wake_forest" /><ref name="pmc_crs_hipec_review" />
 
=== Survival Data from Major Centers ===
 
{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Center/Registry
! style="background:#1a5276; color:white; padding:10px;" | Patients
! style="background:#1a5276; color:white; padding:10px;" | Median OS
! style="background:#1a5276; color:white; padding:10px;" | 5-Year OS
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Multi-institutional (8 centers, Yan et al.)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 405
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''53 months'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''47%'''
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Wake Forest Baptist
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 111
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 39 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | ~40%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 3 US institutions (Alexander et al.)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 211
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 38.4 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 41%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | India tertiary center
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 15
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 27 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 33% (3-year)
|-
| style="padding:10px;" | Meta-analysis (20 studies)
| style="padding:10px;" | 1,047
| style="padding:10px;" | 19–92 months
| style="padding:10px;" | 42%
|}
 
The multi-institutional registry by Yan et al. (2009), published in the ''Journal of Clinical Oncology'' and encompassing 405 patients from eight centers worldwide, remains the landmark dataset. Epithelioid subtype, absence of lymph node metastasis, CC-0/CC-1 resection, and HIPEC itself were all independently associated with improved survival.<ref name="jco_yan" /><ref name="dandell_compensation" />
 
== Who Is a Candidate for Heated Chemotherapy? ==
 
Patient selection is critical for both HITHOC and HIPEC, and treatment decisions should be made at specialized high-volume centers with multidisciplinary expertise.<ref name="pmc_hitoc_german" /><ref name="pmc_crs_hipec_review" />
 
=== HITHOC Candidacy (Pleural Mesothelioma) ===
 
* '''Performance status:''' ECOG 0–1 (95% of German HITOC cohort); Karnofsky index ≥80% (83% of cohort)
* '''Histology:''' Epithelioid strongly preferred (85% of German cohort); biphasic considered selectively; sarcomatoid generally excluded
* '''Disease stage:''' UICC stages I–III (98% of German cohort); stage IV only rarely considered
* '''Surgical goal:''' Macroscopic complete resection must be achievable — HITHOC targets only microscopic residual disease
* '''No distant metastases:''' Extra-thoracic spread is a contraindication
* '''Age:''' Mean age 61.5 years in the German study; no strict cutoff but older patients require careful evaluation<ref name="pmc_hitoc_german" /><ref name="mesonet_eligibility" />
 
=== HIPEC Candidacy (Peritoneal Mesothelioma) ===
 
* '''Performance status:''' ECOG 0–1 preferred; ECOG 2 considered cautiously; ECOG 3 associated with 13× higher mortality hazard
* '''Histology:''' Epithelioid offers best outcomes (38–51 months median OS); biphasic may benefit if CC-0 achievable; sarcomatoid is a contraindication at most centers
* '''PCI score:''' Lower PCI (≤20) strongly preferred — associated with 119-month vs. 39-month median survival
* '''Complete resection:''' CC-0/CC-1 must be achievable; if only CC-2 or CC-3 expected, CRS-HIPEC is generally not performed with curative intent
* '''No extra-abdominal metastases''' or positive lymph nodes
* '''Age:''' Age <60 independently associated with favorable outcomes; average age 55 years at Wake Forest<ref name="wake_forest" /><ref name="droracle_selection" /><ref name="mlc_eligibility" />
 
=== Contraindications ===
 
Heated chemotherapy is generally contraindicated in patients with sarcomatoid histologic subtype, extra-cavitary metastases, poor performance status (ECOG >2), inability to achieve macroscopic complete resection, or significant comorbidities precluding major surgery. For HIPEC specifically, extensive small bowel mesenteric involvement that prohibits adequate cytoreduction is an absolute contraindication. Patients with initially unresectable disease may be referred for neoadjuvant systemic chemotherapy to potentially downstage the tumor before reconsidering surgery.<ref name="pmc_crs_hipec_review" /><ref name="mesoatty_treatment" />
 
== What Are the Complications and Risks? ==
 
=== Renal Toxicity ===
 
Cisplatin-induced nephrotoxicity is the most feared complication specific to heated chemotherapy. In the German HITHOC multicenter study, 12% of patients developed renal insufficiency overall, though only 1.4% required temporary dialysis. High-dose cisplatin (>125 mg/m²) increased the risk 2.7-fold (p=0.006) and was associated with a 12.2-fold higher likelihood of in-hospital mortality (p=0.001). For HIPEC, reported nephrotoxicity rates with cisplatin range from 3.7% to 36%, depending on dosing and renal protection protocols. Sodium thiosulfate, amifostine, and perioperative fluid balancing are used for renal protection, though no standardized protocol exists.<ref name="pmc_nephrotoxicity" /><ref name="amjcr_bidirectional" /><ref name="pmc_hitoc_german" />
 
=== Surgical Complications ===
 
For HITHOC, the German multicenter study reported an overall complication rate of 51%, with surgical revision required in 15% of patients for air leaks, hemothorax, chylothorax, or empyema. Pneumonia occurred in 15%, prolonged air leak (>7 days) in 11%, new atrial fibrillation in 12%, and respiratory insufficiency in 10%. The median ICU stay was 2 days and median hospital stay was 18 days.<ref name="pmc_hitoc_german" /><ref name="dandell_surgery" />
 
For HIPEC, the multi-institutional Yan et al. registry reported an overall complication rate of 46%, with 31% classified as grade 3–4 (severe). A meta-analysis of 20 studies found morbidity rates ranging from 8% to 90%, largely reflecting differences in institutional experience and learning curves.<ref name="jco_yan" /><ref name="pmc_crs_hipec_review" />
 
=== Mortality Rates ===
 
{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Setting
! style="background:#1a5276; color:white; padding:10px;" | 30-Day/In-Hospital Mortality
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HITHOC (German multicenter, n=350)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 3.7%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HITHOC (NCDB, n=365)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 3.2%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HIPEC (Wake Forest, n=111 MPM)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2.7%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HIPEC (8-center registry, n=405)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2.0%
|-
| style="padding:10px;" | HIPEC (3 US centers, n=211)
| style="padding:10px;" | 2.3%
|}
 
A 2025 systematic review found no reported mortality directly attributable to HITHOC-specific complications across all seven included studies. Deaths were attributed to surgical complications or pre-existing comorbidities rather than the heated perfusion itself.<ref name="wjso_systematic" /><ref name="mesonet_surgery" />
 
== What Clinical Trials Are Investigating Heated Chemotherapy? ==
 
=== Active HITHOC Trials ===
 
An active registered trial (NCT05508555) is comparing pleurectomy/decortication with versus without HITHOC using cisplatin at 125 mg/m² infused for 70 minutes at 40–43°C for localized malignant pleural mesothelioma. The 2024 preclinical data demonstrating HITHOC synergy with dual PD-1/CTLA-4 blockade provides strong rationale for clinical combination trials with [[Immunotherapy_for_Mesothelioma|immunotherapy]], which are anticipated.<ref name="springer_egyptian" /><ref name="aacr_immuno" /><ref name="pmc_hitoc_german" />
 
=== Active HIPEC Trials ===
 
Several HIPEC-related trials are ongoing or recently reported. An individualized HIPEC response assessment study is evaluating ex vivo mass response testing to personalize HIPEC agent selection for peritoneal carcinomatosis including mesothelioma. The INTERACT MESO phase I/II trial is investigating intraperitoneal paclitaxel for primary malignant peritoneal mesothelioma. A phase II trial (NTR7060) at Erasmus MC is evaluating adjuvant dendritic cell-based immunotherapy after CRS-HIPEC, with early results showing feasibility and T-cell memory activation. Novel approaches including PIPAC (pressurized intraperitoneal aerosol chemotherapy) are being studied as potential neoadjuvant strategies to downstage initially unresectable peritoneal mesothelioma.<ref name="asco_hipec_personalized" /><ref name="pmc_dc_immunotherapy" /><ref name="pmc_crs_hipec_review" /><ref name="dandell_trials" />
 
== How Does Heated Chemotherapy Connect to Mesothelioma Compensation? ==
 
Patients diagnosed with mesothelioma who undergo HITHOC or HIPEC may be eligible for significant compensation through multiple pathways. The cost of these specialized procedures — which require treatment at experienced high-volume centers — combined with travel, extended hospital stays, and lost income creates substantial financial burden for patients and families.<ref name="dandell_compensation" /><ref name="mlc_compensation" />
 
More than 60 active [[Asbestos_Trust_Funds|asbestos trust funds]] hold over $30 billion for mesothelioma victims, and patients can file claims with multiple trusts simultaneously. Mesothelioma lawsuits have produced some of the largest verdicts in personal injury law. An experienced [[Choosing_a_Mesothelioma_Attorney|mesothelioma attorney]] can help patients navigate the [[Mesothelioma_Claim_Process|claims process]] while they focus on treatment and recovery. Veterans with service-connected asbestos exposure may also qualify for [[Veterans_Benefits|VA disability benefits]] and healthcare coverage.<ref name="mesoatty_claims" /><ref name="mesonet_compensation" />
 
{{Statute Warning}}
 
== Frequently Asked Questions ==
 
=== What is the difference between HITHOC and HIPEC? ===
 
HITHOC (Hyperthermic Intrathoracic Chemotherapy) and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) use the same principle of heated chemotherapy perfusion at 40–43°C but target different body cavities. HITHOC is performed after cytoreductive surgery for '''pleural mesothelioma''' in the chest cavity, typically using cisplatin at 80–125 mg/m2 for 60–90 minutes. HIPEC is performed after cytoreductive surgery for '''peritoneal mesothelioma''' in the abdominal cavity, typically using cisplatin at 200–250 mg/m2 for 90–120 minutes. HIPEC generally produces longer median survival times because peritoneal mesothelioma responds more favorably to this approach than pleural disease.<ref name="pmc_hipec_rationale" /><ref name="pmc_crs_hipec_review" />
 
=== How long does heated chemotherapy surgery take? ===
 
The total operative time for heated chemotherapy procedures varies depending on the extent of cytoreductive surgery required. The perfusion component itself lasts 60–90 minutes for HITHOC and 90–120 minutes for HIPEC. However, the preceding cytoreductive surgery — which removes all visible tumor — can take several additional hours. Extended pleurectomy/decortication with HITHOC may involve diaphragm resection (65.7% of German cohort cases) and pericardium removal (44.6%). For CRS-HIPEC, multiple peritoneal surface resections are performed before the heated perfusion begins. Total surgery plus perfusion typically ranges from 6 to 12 hours.<ref name="pmc_hitoc_german" /><ref name="wake_forest" />
 
=== Who qualifies for heated chemotherapy? ===
 
Ideal candidates for heated chemotherapy have '''epithelioid histology''' (the most common and treatment-responsive subtype), good performance status (ECOG 0–1), and disease where macroscopic complete resection is achievable. For HIPEC specifically, a lower Peritoneal Cancer Index (PCI ≤20) is strongly preferred, as patients with PCI ≤20 achieved 119-month median survival versus 39 months for higher scores. Sarcomatoid histology is generally a contraindication at most centers, and patients must not have distant metastases outside the affected body cavity. Treatment decisions should be made at specialized high-volume centers with multidisciplinary tumor boards.<ref name="pmc_hitoc_german" /><ref name="droracle_selection" />
 
=== What are the major risks of HITHOC and HIPEC? ===
 
The most significant risk specific to heated chemotherapy is '''cisplatin-induced nephrotoxicity''', occurring in approximately 12% of HITHOC patients, though only 1.4% require temporary dialysis. High-dose cisplatin above 125 mg/m2 increases nephrotoxicity risk 2.7-fold. Overall complication rates are approximately 51% for HITHOC and 46% for HIPEC, with 31% classified as severe (grade 3–4) in the HIPEC registry. Common surgical complications include pneumonia (15%), prolonged air leak (11%), and atrial fibrillation (12%) for HITHOC. At experienced high-volume centers, 30-day mortality ranges from 2% to 4% for both procedures.<ref name="pmc_nephrotoxicity" /><ref name="pmc_hitoc_german" /><ref name="jco_yan" />
 
=== How long is the hospital stay and recovery after heated chemotherapy? ===
 
Recovery from heated chemotherapy requires an extended hospital stay. For HITHOC, the German multicenter study reported a median ICU stay of 2 days and median total hospital stay of 18 days. The NCDB analysis found that HITHOC patients had a median hospital stay of 12 days compared to 7 days for surgery without HITHOC. For CRS-HIPEC, hospital stays typically range from 2 to 4 weeks depending on the extent of surgery and complications. Full recovery to normal activity levels generally takes 2 to 3 months, though patients with extensive surgery involving diaphragm or pericardium resection may require longer rehabilitation.<ref name="pmc_hitoc_german" /><ref name="jtd_ncdb" />
 
=== What survival rates can patients expect with heated chemotherapy? ===
 
Survival outcomes vary significantly based on disease type, completeness of surgery, and histologic subtype. For '''pleural mesothelioma''' with HITHOC, the largest study showed 20.5-month median survival, with epithelioid patients in a pilot trial achieving 45 months. For '''peritoneal mesothelioma''' with CRS-HIPEC, the landmark 405-patient registry reported 53-month median survival and 47% 5-year survival. The best outcomes are seen in patients achieving complete cytoreduction — at Wake Forest, CC-0/CC-1 patients with cisplatin HIPEC achieved a median survival of 127 months (over 10 years).<ref name="jtd_ncdb" /><ref name="jco_yan" /><ref name="wake_forest" />
 
=== Does insurance cover HITHOC and HIPEC procedures? ===
 
HIPEC for peritoneal mesothelioma is increasingly covered by major insurance providers as it has become an established standard of care at specialized centers. HITHOC for pleural mesothelioma may require additional authorization as it is still considered investigational by some payers. Both procedures are complex and expensive, involving extended hospital stays and specialized surgical teams available only at high-volume centers. Patients diagnosed with mesothelioma caused by asbestos exposure may be eligible for compensation through [[Asbestos_Trust_Funds|asbestos trust funds]], lawsuits, or [[Veterans_Benefits|VA benefits]] that can help cover treatment costs. An experienced [[Choosing_a_Mesothelioma_Attorney|mesothelioma attorney]] can help navigate these options.<ref name="dandell_compensation" /><ref name="mlc_compensation" />
 
=== Are there newer alternatives to cisplatin for heated chemotherapy? ===
 
While '''cisplatin''' remains the primary agent for both HITHOC and HIPEC, research is exploring alternatives and combinations. The RENAPE multicenter study demonstrated that '''dual-agent regimens''' (cisplatin plus doxorubicin) achieved significantly better overall survival than single-agent protocols (HR 0.54) without increased major morbidity. '''Carboplatin''' is used occasionally as an alternative, and '''PIPAC''' (Pressurized Intraperitoneal Aerosol Chemotherapy) is being studied as a potential neoadjuvant strategy. An emerging approach uses '''ex vivo mass response testing''' to personalize HIPEC agent selection for individual patients. Dendritic cell-based immunotherapy after CRS-HIPEC has shown feasibility in early-phase trials.<ref name="pmc_crs_hipec_review" /><ref name="asco_hipec_personalized" /><ref name="pmc_dc_immunotherapy" />
 
== Get Help ==
 
Mesothelioma patients and families can connect with experienced legal and medical advocates:
 
* [https://dandell.com/contact-us/ Danziger & De Llano] provides free case evaluations and can connect families with specialized treatment centers — call (866) 222-9990
* [https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Lawyer Center] offers resources on treatment options and legal rights
* [https://mesothelioma.net/mesothelioma-treatment/ Mesothelioma.net] provides comprehensive information on heated chemotherapy and treatment options
 
== Quick Statistics ==
 
* Approximately '''3,300 new peritoneal mesothelioma cases''' are diagnosed worldwide each year, with CRS-HIPEC now the standard-of-care treatment at specialized centers<ref name="pmc_crs_hipec_review" />
* The '''mean Peritoneal Cancer Index''' at first CRS-HIPEC was 18.7 across 111 patients at Wake Forest Baptist Medical Center over 28 years of experience<ref name="wake_forest" />
* '''Extended P/D''' was the most common surgical approach in the German HITHOC cohort, used in 75% of 350 patients, followed by standard P/D (22%) and EPP (3%)<ref name="pmc_hitoc_german" />
* '''Diaphragm resection''' was required in 65.7% and '''pericardium resection''' in 44.6% of German HITHOC cases, reflecting the advanced disease stage at presentation<ref name="pmc_hitoc_german" />
* '''Median hospital stay''' for HITHOC patients was 18 days with a median ICU stay of 2 days in the German multicenter series<ref name="pmc_hitoc_german" />
* A '''meta-analysis of 20 CRS-HIPEC studies''' encompassing 1,047 patients reported morbidity rates ranging from 8% to 90%, reflecting wide variation in institutional experience<ref name="pmc_crs_hipec_review" />
* '''Three US institutions''' (Alexander et al.) reported 38.4-month median survival and 41% 5-year OS across 211 peritoneal mesothelioma patients treated with CRS-HIPEC<ref name="pmc_alexander" />
* The '''HITHOC 30-day mortality paradox''' — despite longer hospital stays (12 vs 7 days), HITHOC patients had lower 30-day mortality (3.2% vs 6.0%, p=0.017) in the NCDB analysis<ref name="jtd_ncdb" />
* An '''Indian tertiary center''' reported 33% 3-year survival across 15 peritoneal mesothelioma patients, demonstrating CRS-HIPEC feasibility in developing nations<ref name="cureus_india" />
* A '''2025 systematic review''' of 7 HITHOC studies found no mortality directly attributable to the heated perfusion itself — all deaths were from surgical complications or comorbidities<ref name="wjso_systematic" />
 
== Related Resources ==
 
* [[Pleurectomy_and_Decortication|Pleurectomy and Decortication]]
* [[Immunotherapy_for_Mesothelioma|Immunotherapy for Mesothelioma]]
* [[Treatment_Options|Mesothelioma Treatment Options]]
* [[Clinical_Trials|Mesothelioma Clinical Trials]]
* [[Mesothelioma_Treatment_Centers|Mesothelioma Treatment Centers]]
* [[Mesothelioma_Diagnosis_and_Staging|Mesothelioma Diagnosis and Staging]]
 
<span data-nosnippet class="noai-content">
{{CTA Box|}}
</span>
 
== References ==
<references>
<ref name="pmc_hipec_rationale">[https://pmc.ncbi.nlm.nih.gov/articles/PMC2999165/ Hyperthermic Intraperitoneal Chemotherapy: Rationale and Technique], PMC / National Library of Medicine</ref>
<ref name="pmc_optimal_hipec">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11588639/ Optimal Hyperthermic Intraperitoneal Chemotherapy Regimen], PMC / National Library of Medicine</ref>
<ref name="pmc_hithoc_mech">[https://pmc.ncbi.nlm.nih.gov/articles/PMC8263861/ Hyperthermic Intrathoracic Chemotherapy (HITHOC): Mechanisms and Clinical Application], PMC / National Library of Medicine</ref>
<ref name="pmc_hitoc_german">[https://pmc.ncbi.nlm.nih.gov/articles/PMC8470046/ Hyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery: German Multicenter Study of 350 Patients], PMC / National Library of Medicine</ref>
<ref name="pmc_hithoc_review">[https://pmc.ncbi.nlm.nih.gov/articles/PMC8263861/ Hyperthermic Intrathoracic Chemotherapy (HITHOC)], PMC / National Library of Medicine</ref>
<ref name="mdpi_hitoc_2024">[https://www.mdpi.com/2072-6694/16/8/1587 Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy], MDPI Cancers (2024)</ref>
<ref name="jtd_ncdb">[https://jtd.amegroups.com/article/view/80136/html Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) During Resection of Pleural Mesothelioma on Patient Survival], Journal of Thoracic Disease (2023)</ref>
<ref name="wjso_systematic">[https://wjso.biomedcentral.com/articles/10.1186/s12957-025-03748-8 Hyperthermic Intrathoracic Chemotherapy in Patients with Malignant Pleural Mesothelioma: A Systematic Review], World Journal of Surgical Oncology (2025)</ref>
<ref name="medrxiv_pilot">[https://medrxiv.org/lookup/doi/10.1101/2021.11.27.21265291 Comparison of VATS P/D Surgery plus HITHOC with VATS Talc Pleurodesis for MPM: A Randomized Pilot Study], medRxiv (2021)</ref>
<ref name="springer_egyptian">[https://link.springer.com/10.1007/s13304-024-01986-1 Effect of Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for MPM: A Comparative Study], Updates in Surgery (2024)</ref>
<ref name="pmc_egyptian">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11628442/ Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for Malignant Pleural Mesothelioma], PMC / National Library of Medicine (2024)</ref>
<ref name="aacr_immuno">[https://aacrjournals.org/cancerimmunolres/article/13/2/185/751253/Hyperthermic-Intrathoracic-Chemotherapy-Modulates Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma], Cancer Immunology Research (2024)</ref>
<ref name="pmc_crs_hipec_review">[https://pmc.ncbi.nlm.nih.gov/articles/PMC6511620/ Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma], PMC / National Library of Medicine</ref>
<ref name="wake_forest">[https://pmc.ncbi.nlm.nih.gov/articles/PMC10249750/ Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center], Annals of Surgical Oncology (2023)</ref>
<ref name="jco_yan">[https://ascopubs.org/doi/10.1200/JCO.2009.23.9640 Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience], Journal of Clinical Oncology (2009)</ref>
<ref name="pmc_alexander">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3734959/ Treatment Factors Associated with Long-Term Survival After CRS and Regional Chemotherapy for Malignant Peritoneal Mesothelioma], PMC / National Library of Medicine</ref>
<ref name="cureus_india">[https://www.cureus.com/articles/312878 Cytoreductive Surgery and HIPEC for Peritoneal Mesothelioma: Outcomes from a Tertiary Cancer Care Center in India], Cureus</ref>
<ref name="pmc_nephrotoxicity">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11242517/ Nephrotoxicity Associated with Cytoreductive Surgery Combined with HIPEC], PMC / National Library of Medicine</ref>
<ref name="amjcr_bidirectional">[https://amjcaserep.com/abstract/full/idArt/938192 Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide], American Journal of Case Reports</ref>
<ref name="droracle_selection">[https://www.droracle.ai/articles/655039/what-qualifies-a-patient-for-hyperthermic-intraperitoneal-chemotherapy-hipec Patient Selection Criteria for HIPEC], Dr. Oracle</ref>
<ref name="asco_hipec_personalized">[https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3132 Ex Vivo Assessment of Cellular Mass Response for Personalized HIPEC Agent Selection], ASCO Abstract (2024)</ref>
<ref name="pmc_dc_immunotherapy">[https://pmc.ncbi.nlm.nih.gov/articles/PMC10401259/ Adjuvant Dendritic Cell-Based Immunotherapy After CRS and HIPEC for Malignant Peritoneal Mesothelioma: Phase II Trial], PMC / National Library of Medicine</ref>
<ref name="dandell_treatment">[https://dandell.com/mesothelioma-treatment/ Mesothelioma Treatment Options], Danziger & De Llano</ref>
<ref name="dandell_compensation">[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>
<ref name="dandell_surgery">[https://dandell.com/mesothelioma-surgery/ Mesothelioma Surgery Options], Danziger & De Llano</ref>
<ref name="dandell_peritoneal">[https://dandell.com/peritoneal-mesothelioma/ Peritoneal Mesothelioma], Danziger & De Llano</ref>
<ref name="dandell_trials">[https://dandell.com/mesothelioma-clinical-trials/ Mesothelioma Clinical Trials], Danziger & De Llano</ref>
<ref name="mlc_treatment">[https://mesotheliomalawyercenter.org/mesothelioma/treatment/ Mesothelioma Treatment Options], Mesothelioma Lawyer Center</ref>
<ref name="mlc_surgery">[https://mesotheliomalawyercenter.org/mesothelioma/treatment/surgery/ Mesothelioma Surgery], Mesothelioma Lawyer Center</ref>
<ref name="mlc_peritoneal">[https://mesotheliomalawyercenter.org/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma], Mesothelioma Lawyer Center</ref>
<ref name="mlc_compensation">[https://mesotheliomalawyercenter.org/compensation/ Mesothelioma Compensation Guide], Mesothelioma Lawyer Center</ref>
<ref name="mlc_eligibility">[https://mesotheliomalawyercenter.org/mesothelioma/treatment/eligibility/ Treatment Eligibility for Mesothelioma Patients], Mesothelioma Lawyer Center</ref>
<ref name="mesonet_treatment">[https://mesothelioma.net/mesothelioma-treatment/ Mesothelioma Treatment], Mesothelioma.net</ref>
<ref name="mesonet_eligibility">[https://mesothelioma.net/mesothelioma-treatment/eligibility/ Treatment Eligibility and Candidacy], Mesothelioma.net</ref>
<ref name="mesonet_surgery">[https://mesothelioma.net/mesothelioma-surgery/ Mesothelioma Surgery Options], Mesothelioma.net</ref>
<ref name="mesonet_compensation">[https://mesothelioma.net/mesothelioma-compensation/ Mesothelioma Compensation Guide], Mesothelioma.net</ref>
<ref name="mesoatty_treatment">[https://mesotheliomaattorney.com/mesothelioma/treatment/ Mesothelioma Treatment Overview], MesotheliomaAttorney.com</ref>
<ref name="mesoatty_claims">[https://mesotheliomaattorney.com/asbestos-trust-funds/ Asbestos Trust Funds], MesotheliomaAttorney.com</ref>
</references>
 
[[Category:Mesothelioma]]
[[Category:Medical]]
[[Category:Treatment]]
[[Category:Surgery]]
[[Category:Chemotherapy]]
[[Category:Clinical Trials]]
[[Category:Peritoneal Mesothelioma]]
[[Category:Pleural Mesothelioma]]

Latest revision as of 13:41, 23 April 2026

Redirect to:

Retrieved from "https://wikimesothelioma.com/w/index.php?title=Heated_Chemotherapy_HITHOC_and_HIPEC&oldid=2378"